CXCL2 and neoplasm: While S100A9, IL-10, and Cxcl2 expression was reduced in a-PD-L1-treated 2F8c tumors compared to tumor controls (Figure 4E), no reduction was detected between a-PD-L1-treated and control Egfl6+ tumors (Figure 4F).